Felbamate

For research use only. Not for therapeutic Use.

  • CAT Number: A000408
  • CAS Number: 25451-15-4
  • Molecular Formula: C11H14N2O4
  • Molecular Weight: 238.2
  • Purity: ≥95%
Inquiry Now

Felbamate is an anti-epileptic drug used in the treatment of epilepsy. Felbamate has been proposed to a unique dual mechanism of action as a positive modulator of GABAA receptors and as a blocker of NMDA receptors, particularly isoforms containing the NR2B subunit. Although it is clear that felbamate does cause pharmacological inhibition of NMDA receptors, the relevance of NMDA receptor blockade as a strategy for the treatment of human epilepsy has been questioned. Therefore, the importance of the effects of felbamate on NMDA receptors to its therapeutic action in epilepsy is uncertain.


Catalog Number A000408
CAS Number 25451-15-4
Synonyms

25451-15-4; Felbatol; 2-Phenylpropane-1,3-diyl dicarbamate; 2-Phenyl-1,3-propanediol dicarbamate; Felbamyl

Molecular Formula C11H14N2O4
Purity ≥95%
Target NMDA Receptor
Solubility Soluble in DMSO > 10 mM
Storage -20°C
InChI 1S/C11H14N2O4/c12-10(14)16-6-9(7-17-11(13)15)8-4-2-1-3-5-8/h1-5,9H,6-7H2,(H2,12,14)(H2,13,15)
InChIKey WKGXYQFOCVYPAC-UHFFFAOYSA-N
SMILES C1=CC=C(C=C1)C(COC(=O)N)COC(=O)N
Reference

1: Shi LL, Dong J, Ni H, Geng J, Wu T. Felbamate as an add-on therapy for
refractory partial epilepsy. Cochrane Database Syst Rev. 2017 Jul 18;7:CD008295.
doi: 10.1002/14651858.CD008295.pub4. Review. PubMed PMID: 28718506.
<br>

2: Shah YD, Singh K, Friedman D, Devinsky O, Kothare SV. Evaluating the safety
and efficacy of felbamate in the context of a black box warning: A single center
experience. Epilepsy Behav. 2016 Mar;56:50-3. doi: 10.1016/j.yebeh.2016.01.006.
Epub 2016 Jan 30. PubMed PMID: 26828692.
<br>

3: Mishal NM, Arkilo D, Tang J, Crawford JR, Wang SG. A Potential Role for
Felbamate in TSC- and NF1-Related Epilepsy: A Case Report and Review of the
Literature. Case Rep Neurol Med. 2015;2015:960746. doi: 10.1155/2015/960746. Epub
2015 Oct 22. PubMed PMID: 26579319; PubMed Central PMCID: PMC4633543.
<br>

4: Thakkar K, Billa G, Rane J, Chudasama H, Goswami S, Shah R. The rise and fall
of felbamate as a treatment for partial epilepsy–aplastic anemia and hepatic
failure to blame? Expert Rev Neurother. 2015;15(12):1373-5. doi:
10.1586/14737175.2015.1113874. Epub 2015 Nov 13. PubMed PMID: 26566191.
<br>

5: Coorg R, Weisenberg JL. Successful Treatment of Electrographic Status
Epilepticus of Sleep With Felbamate in a Patient With SLC9A6 Mutation. Pediatr
Neurol. 2015 Dec;53(6):527-31. doi: 10.1016/j.pediatrneurol.2015.07.007. Epub
2015 Jul 22. PubMed PMID: 26421989.

<br>
6: Shi LL, Dong J, Ni H, Geng J, Wu T. Felbamate as an add-on therapy for
refractory epilepsy. Cochrane Database Syst Rev. 2014 Jul 18;(7):CD008295. doi:
10.1002/14651858.CD008295.pub3. Review. Update in: Cochrane Database Syst Rev.
2017 Jul 18;7:CD008295. PubMed PMID: 25036694.
<br>

7: Heyman E, Levin N, Lahat E, Epstein O, Gandelman-Marton R. Efficacy and safety
of felbamate in children with refractory epilepsy. Eur J Paediatr Neurol. 2014
Nov;18(6):658-62. doi: 10.1016/j.ejpn.2014.05.005. Epub 2014 May 22. PubMed PMID:
24906615.
<br>

8: Ghousheh AI, Groth TW, Fryjoff KM, Wille DF, Mandel NS, Roddy JT, Durkee CT.
Urolithiasis in patients on high dose felbamate. J Urol. 2013 May;189(5):1865-9.
doi: 10.1016/j.juro.2012.12.032. Epub 2012 Dec 21. PubMed PMID: 23262038.
<br>

9: Shi LL, Dong J, Ni H, Geng J, Wu T. Felbamate as an add-on therapy for
refractory epilepsy. Cochrane Database Syst Rev. 2011 Jan 19;(1):CD008295. doi:
10.1002/14651858.CD008295.pub2. Review. Update in: Cochrane Database Syst Rev.
2014;7:CD008295. PubMed PMID: 21249704.

<br>
10: Hansen RJ, Samber BJ, Gustafson DL. Rapid and sensitive LC-MS/MS method for
determination of felbamate in mouse plasma and tissues and human plasma. J
Chromatogr B Analyt Technol Biomed Life Sci. 2010 Dec 15;878(32):3432-6. doi:
10.1016/j.jchromb.2010.10.006. Epub 2010 Oct 16. PubMed PMID: 21081288; PubMed
Central PMCID: PMC4278804.

Request a Quote